QUEBEC CITY, May 14, 2012 /CNW/ - Medicago Inc. (TSX: MDG), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that the Company will host an Investor Day event on May 30, 2012, at the Indigo Hotel, 151 Tatum Drive, Durham, North Carolina The meeting, which also will be webcast live, will begin promptly at 12:30 p.m. Eastern Time and end at approximately 1:30 p.m. Eastern Time.
The Investor Day event will feature presentations from Medicago executives including: Andy Sheldon, Chief Executive Officer; Pierre Labbe, Chief Financial Officer; and Mike Wanner, Executive Vice President of Operations. The presentation will include discussions on the Company's results, business strategy and outlook into 2013.
Institutional investors and analysts interested in attending the Investor Day event should contact Catherine Love, Medicago Investor Relations, to register via telephone at (418) 658-9393 ext. 156 or email at firstname.lastname@example.org. Those attending in person will be invited for a tour of the Medicago commercial production facility in Research Triangle Park, Durham, NC.
Interested parties may listen to the live, audio webcast of the event by visiting the Company's website at http://www.medicago.com/Investors/Events-Presentations. To listen by phone, please dial (647) 427-7450 or 1- 888-231-8191(toll-free North America).
Following the call, an audio archive of the webcast will be available on the Medicago website. A replay will also be available by phone until June 30, 2012, by dialing 1-855-859-2056, code 77779960.
Medicago is a clinical-stage biopharmaceutical company developing novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The Company is committed to providing highly effective and competitive vaccines and therapeutic proteins based on its proprietary VLP and manufacturing technologies. Medicago is a worldwide leader in the development of VLP vaccines using a transient expression system which produces recombinant vaccine antigens in plants. This technology has potential to offer more potent vaccines with speed and cost advantages over competitive technologies, enabling the development of a vaccine for testing in approximately one month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic, and supply large volumes of vaccine antigens to the world market. Medicago also intends to expand development into other areas such as biosimilars and biodefense products where the benefits of our technologies can make a significant difference. Additional information about Medicago is available at www.medicago.com.
Forward Looking Statements
This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with Medicago's business and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions to the extent they relate to Medicago or its management. The forward-looking statements are not historical facts, but reflect Medicago's current expectations regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations, including the matters discussed under "Risk Factors and Uncertainties" in Medicago's Annual Information Form filed on March 29, 2012, with the regulatory authorities. Medicago assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.
For further information:
President and CEO
(418) 658-9393 ext.156